Pancreas transplantation for diabetes mellitus: A guide to recipient selection and optimum immunosuppression

BioDrugs

Volumn 10, Issue 5, 1998, Pages 347-357

  Stratta, Robert J ^a   Alloway, Rita R ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRAP; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; SYNTHETIC PEPTIDE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETOGENESIS; DRUG FORMULATION; GASTROINTESTINAL TOXICITY; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NEUROTOXICITY; PANCREAS TRANSPLANTATION; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECIPIENT; SIDE EFFECT;

EID: 0031788194     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810050-00002     Document Type: Article

References (62)

1. Stratta RJ, Larsen JL, Cushing K. Pancreas transplantation for diabetes mellitus. Ann Rev Med 1995; 46: 281-98
2. Stratta RJ, Taylor RJ, Wahl TO, et al. Recipient selection and evaluation for vascularized pancreas transplantation. Transplantation 1993; 55: 1090-6
3. Stratta RJ, Taylor RJ, Ozaki CF, et al. A comparative analysis of results in morbidity in type I diabetics undergoing preemptive versus post-dialysis combined pancreas-kidney transplantation. Transplantation 1993; 55: 1097-103
4. Stratta RJ, Weide LG, Sindhi R, et al. Solitary pancreas transplantation: Experience with 62 consecutive cases. Diabetes Care 1997; 209 (3): 362-8
5. Brennan DC, Stratta RJ, Lowell JA, et al. Cyclosporine challenge in the decision of combined kidney-pancreas versus solitary pancreas transplantation. Transplantation 1994; 57: 1606-11
6. Gruessner A, Sutherland DER. Pancreas transplantation in the United States (US) and non-US as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). In: Cecka JM, Terasaki PI, editors. Clinical Transplants 1996. Los Angeles: UCLA Tissue Typing Laboratory, 1997: 47-67
7. Stratta RJ. Analysis of mortality after pancreas transplantation. Transplant Proc 1998; 30 (2): 283
8. Stratta RJ, Taylor RJ, Weide LG, et al. A prospective randomized trial of OKT3 versus ATGAM induction therapy in pancreas transplant recipients. Transplant Proc 1996; 28 (2): 927-8
9. Knechtle SJ, Pirsch JD, Groshek M, et al. OKT3 versus ALG induction therapy in combined pancreas-kidney transplantation. Transplant Proc 1991; 23: 1581-2
10. Sutherland DER, Moudry-Munns KC, Gruessner A. Pancreas transplant outcome with or without biological anti-T cell therapy for induction immunosuppression with use of cyclosporine. Transplant Proc 1994; 26: 2752-5
11. Wadstrom J, Brekke B, Wramner L, et al. Triple versus quadruple induction immunosuppression in pancreas transplantation. Transplant Proc 1995; 27: 1317-8
12. Brayman KL, Egidi MF, Naji AL, et al. Is induction therapy necessary for successful simultaneous pancreas and kidney transplantation in the cyclosporine era? Transplant Proc 1994; 26: 2525-7
13. Ilner WD, Theodorakis J, Abendroth D, et al. Quadruple-drug induction therapy in combined renal and pancreatic transplantation: OKT3 versus ATG. Transplant Proc 1990; 22: 1586-7
14. Rosenberg L. Pancreas transplantation with ATG versus OKT3. Transplant Proc 1997; 24 Suppl. 7A: 35S-6S
15. Gruessner RWG, Troppmann C, Barrou B. Assessment of donor and recipient risk factors on pancreas transplant outcome. Transplant Proc 1994; 26 (2): 437-8
16. Viste A, Moudry-Munns K, Sutherland DER. Prognostic risk factors for graft failure following pancreas transplantation: results of multivariate analysis of data from the International Pancreas Transplant Registry. Transpl Int 1990; 3: 98-102
17. Brayman KL, Sutherland DER. Factors leading to improved outcome following pancreas transplantation - the influence of immunosuppression and HLA matching. Transplant Proc 1992; 24 Suppl. 2: 91-5
18. Shapiro ME, Abrams JM, Brown RS, et al. Successful pancreas-renal transplantation without anti-T cell antibody induction. Transplant Proc 1995; 27 (6): 3087-8
19. Corry RJ, Egidi MF, Sugitani A, et al. Tacrolimus without anti-lymphocyte induction therapy prevents pancreas loss from rejection in 100 consecutive patients [abstract]. Acta Diabetol 1997; 34 (8): 125
20. Van Der Pijl JW, Srivastava N, Denouel J, et al. Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis. Transplantation 1996; 62: 456-62
21. Storck M, Mickley V, Steinbach G, et al. Cyclosporine resorption in diabetic patients after simultaneous pancreas and kidney transplantation. Transplant Proc 1995; 27: 3094-5
22. Lang J, Garnier JL, Faure JL, et al. Cyclosporine pharmacokinetics in diabetic patients after kidney and pancreas transplantation. Clin Transpl 1989; 3: 1-4
23. Serafinowicz A, Gaciong Z, Baczkowska T, et al. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus treated with Sandimmun and Sandimmun Neoral. Transplant Proc 1996; 28 (6): 3140-1
24. Dawidson I, Ar'rajab A, Lu C, et al. Cyclosporine blood levels predict the likelihood of rejection and toxicity after simultaneous pancreas-kidney transplantation. Transplant Proc 1995; 27 (1): 1324-6
25. Rigotti P, Cadrobbi R, Baldan N, et al. Neoral versus Sandimmun in kidney-pancreas transplantation. Transplant Proc 1997; 29: 2924-6
26. Chapman JR, O'C'onnell PJ, Bovington KJ, et al. Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplants using a microemulsion formulation. Transplantation 1996; 61: 1699-704
27. Gruessner RWG, Burke GW, Stratta RJ, et al. Multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996; 61: 261-73
28. Gruessner RWG. Tacrolimus in pancreas transplantation: a multi-center analysis. Clin Transpl 1997; 11: 299-312
29. Hariharan S, Munda R, Cavallo T, et al. Rescue therapy with tacrolimus after combined kidney-pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation 1096; 61: 1161-5
30. Stratta RJ, Taylor RJ, Castaldo P, et al. FK506 induction and rescue therapy in pancreas transplant recipients. Transplant Proc 1996; 28: 1001-2
31. Bartlett ST, Schweitzer EJ, Johnson LB, et al. Equivalent success of simultaneous pancreas-kidney and solitary pancreas transplantation: a prospective trial of tacroliumus immunosuppression with percutaneous biopsy. Ann Surg 1996; 224 (4): 440-9
32. Teraoka S, Babazono T, Koike T, et al. Effect of rescue therapy using FK506 on relapsing rejection after combined pancreas and kidney transplantation. Transplant Proc 1995; 27: 1335-9
33. Shaffer D, Simpson MA, Conway P, et al. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). Transplantation 1995; 59: 1063-6
34. Becker J, Witzke O, Friedrich J, et al. Rescue therapy with tacrolimus in simultaneous pancreas/kidney transplantation. Transpl Int 1997; 10: 51-4
35. Demirbas A, Ciancio G, Burke G, et al. FK506 in simultaneous pancreas/kidney transplantation: the University of Miami experience. Transplant Proc 1997; 29: 2903
36. Alloway RR, Russell WC, Gaber LW, et al. Conversion from cyclosporine to tacrolimus in kidney, kidney-pancreas, and pancreas alone transplant recipients: the Memphis experience. Transplant Proc 1996; 28 (2): 995-7
37. Gruessner RWG, Sutherland DER, Najarian JS, et al. Pancreas transplantation for nonuremic patients with labile insulin dependent diabetes mellitus. Transplantation 1997; 64: 1572-7
38. Allison AC, Eugui EM. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transpl 1993; 7: 96-112
39. Sollinger HW. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate Mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-32
40. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345 (5): 1321-5
41. Stratta RJ, Taylor RJ, Gill IS, et al. Mycophenolate Mofetil (MMF) induction and conversion therapy in pancreas transplant recipients. 15th Annual Scientific Meeting of the American Society of Transplant Physicians; 1996 May 26-20; Dallas
42. Elkhammas EA, Yilmaz S, Henry ML, et al. Combined kidney/pancreas transplantation: comparison of mycophenolate mofetil versus azathioprine [abstract]. Acta Diabetol 1997; 34 (8): 161
43. Odorico JS, Pirsch JD, Knechtle SJ, et al. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation [abstract]. Transplantation 1998; 65: 240 (645A)
44. Gritsch HA, Egidi MF, Sugitani A, et al. Comparison of azathioprine and mycophenolate mofetil in pancreas transplantation [abstract]. Acta Diabetol 1997; 34 (8): 162
45. Marcos A, Ham JM, Shelden SL, et al. Mycophenolate mofetil is associated with decreased incidence in severity of acute cellular rejection following simultaneous kidney/pancreas transplant. 16th Annual Scientific Meeting of the American Society of Transplant Physicians; 1997 May 10-14; Chicago
46. Stratta RJ, FK/MMF Multi-center Study Group. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. Transplant Proc 1997; 29: 654-5
47. Gruessner RWG, Sutherland DER, Drangstveit MB, et al. Mycophenolate mofetil in pancreas transplantation. Transplantation 1998; 66: 318-23
48. Stegall MD, Simon M, Wachs M, et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation 1997; 64: 1695-1700
49. Kaufman DB, DuPuis J, Abecassis M, et al. Results with tacrolimus/mycophenolate mofetil primary maintenance immunosuppression in simultaneous pancreas/kidney transplantation [abstract]. Acta Diabetol 1997; 34 (8): 120
50. Busing M, Martin D, Schulz T, et al. Mycophenolate mofetil/tacrolimus/single shot ATG versus azathioprine/cyclosporine in pancreas-kidney transplantation: results of a prospective randomized single-center study. Transplant Proc 1998; 30: 516-7
51. Bruce DS, Woodle ES, Newell KA, et al. Effects of tacrolimus, mycophenolate mofetil, and microemulsified cyclosporine on rejection incidence in synchronous pancreas/kidney transplantation. Transplant Proc 1998; 30: 507-8
52. Kahl A, Bechstein WO, Platz K, et al. First results with a quadruple therapy regimen including tacrolimus and mycophenolate mofetil in patients after combined pancreas and kidney transplantation. Transplant Proc 1998; 30: 505-6
53. Lee CM, Scandling JD, Pavlakis M, et al. FK506 and mycophenolate mofetil: the superior strategy for simultaneous pancreas-kidney patients. 23rd Annual Scientific Meeting of the American Society of Transplant Surgeons; 1997 May 14-16; Chicago
54. Reddy KS, Stratta RJ, Shokouh-Amiri MH, et al. Simultaneous kidney-pancreas transplantation without anti-lymphocyte induction [abstract]. Transplantation 1998; 65: 251 (691A)
55. Zucker K, Rosen A, Tsaroucha A, et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and Cellcept in combination therapy. Transplant Proc 1997; 29: 334-6
56. Pirsch JD, Bekersky I, Vincenti F, et al. Co-administration of tacrolimus and mycophenolate mofetil may result in higher MPA exposure. 16th Annual Scientific Meeting of the American Society of Transplant Physicians; 1997 May 11-14; Chicago
57. Stratta RJ, Taylor RJ, Bynon JS, et al. Viral prophylaxis in combined pancreas-kidney transplant recipients. Transplantation 1994; 57: 506-12
58. Cantarovich D, Palneau J, Couderc JP, et al. Maintenance immunosuppression without corticosteroids following combined pancreas and kidney transplantation. Transplant Proc 1991; 23 (4): 2224-5
59. Hricik DE, Bartucci MR, Mayes JT, et al. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54: 868-71
60. Milde FK, Hart LK, Zehr PS, Pancreatic transplantation: impact on the quality of life of diabetic renal transplant recipients. Diabetes Care 1995; 18 (1): 93-5
61. Hathaway DK, Hartwig MS, Crom DB, et al. Identification of quality-of-life outcomes distinguishing diabetic kidney-alone and pancreas-kidney recipients. Transplant Proc 1995; 27 (6): 3065-6
62. Zehrer CI, Gross CR. Quality-of-life of pancreas transplant recipients. Diabetologia 1991; 34 Suppl. 1: S145-9